IBRX Stock Forecast: 2026 Target $13?
Examine IBRX stock price swings, biotech earnings, technical analysis, and 2026 forecast. Is IBRX stock a buy? Assess valuation risks and immunotherapy pipeline now. Introduction ImmunityBio Inc. (IBRX stock) develops cancer immunotherapies and vaccines. Its lead asset ANKTIVA targets bladder cancer with T-cell activation technology. Investors monitor IBRX stock amid FDA approvals and clinical volatility. … Read more